Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid

Elizabeth M. Hadac, Elizabeth J. Kelly, Stephen J Russell

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The feasibility of using a nonviral vector formulation to initiate an oncolytic viral infection has not been previously demonstrated. We therefore sought to determine whether infectious nucleic acid (INA) could be used in place of virus particles to initiate an oncolytic picornavirus infection in vivo. Infectious RNA encoding coxsackievirus A21 (CVA21) was transcribed from plasmid DNA using T7 polymerase. Within 48 hours of injecting this RNA into KAS6/1 myeloma xenografts, high titers of infectious CVA21 virions were detected in the bloodstream. Tumors regressed rapidly thereafter and mice developed signs of myositis. At euthanasia, CVA21 was recovered from regressing tumors and from skeletal muscles. Treatment outcomes were comparable following intratumoral injection of naked RNA or fully infectious CVA21 virus. Dose-response studies showed that an effective oncolytic infection could be established by intratumoral injection of 1μg of infectious RNA. The oncolytic infection could also be initiated by intravenous injection of infectious RNA. Our study demonstrates that INA is a highly promising alternative drug formulation for oncolytic virotherapy.

Original languageEnglish (US)
Pages (from-to)1041-1047
Number of pages7
JournalMolecular Therapy
Volume19
Issue number6
DOIs
StatePublished - 2011

Fingerprint

Heterografts
Nucleic Acids
Enterovirus
RNA
Virion
Picornaviridae Infections
Oncolytic Virotherapy
Drug Compounding
Injections
Myositis
Euthanasia
Virus Diseases
Infection
Intravenous Injections
Neoplasms
Skeletal Muscle
Plasmids
Viruses
DNA

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid. / Hadac, Elizabeth M.; Kelly, Elizabeth J.; Russell, Stephen J.

In: Molecular Therapy, Vol. 19, No. 6, 2011, p. 1041-1047.

Research output: Contribution to journalArticle

Hadac, Elizabeth M. ; Kelly, Elizabeth J. ; Russell, Stephen J. / Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid. In: Molecular Therapy. 2011 ; Vol. 19, No. 6. pp. 1041-1047.
@article{ecb33786fc7e46e4ad1172332039be0d,
title = "Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid",
abstract = "The feasibility of using a nonviral vector formulation to initiate an oncolytic viral infection has not been previously demonstrated. We therefore sought to determine whether infectious nucleic acid (INA) could be used in place of virus particles to initiate an oncolytic picornavirus infection in vivo. Infectious RNA encoding coxsackievirus A21 (CVA21) was transcribed from plasmid DNA using T7 polymerase. Within 48 hours of injecting this RNA into KAS6/1 myeloma xenografts, high titers of infectious CVA21 virions were detected in the bloodstream. Tumors regressed rapidly thereafter and mice developed signs of myositis. At euthanasia, CVA21 was recovered from regressing tumors and from skeletal muscles. Treatment outcomes were comparable following intratumoral injection of naked RNA or fully infectious CVA21 virus. Dose-response studies showed that an effective oncolytic infection could be established by intratumoral injection of 1μg of infectious RNA. The oncolytic infection could also be initiated by intravenous injection of infectious RNA. Our study demonstrates that INA is a highly promising alternative drug formulation for oncolytic virotherapy.",
author = "Hadac, {Elizabeth M.} and Kelly, {Elizabeth J.} and Russell, {Stephen J}",
year = "2011",
doi = "10.1038/mt.2011.68",
language = "English (US)",
volume = "19",
pages = "1041--1047",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid

AU - Hadac, Elizabeth M.

AU - Kelly, Elizabeth J.

AU - Russell, Stephen J

PY - 2011

Y1 - 2011

N2 - The feasibility of using a nonviral vector formulation to initiate an oncolytic viral infection has not been previously demonstrated. We therefore sought to determine whether infectious nucleic acid (INA) could be used in place of virus particles to initiate an oncolytic picornavirus infection in vivo. Infectious RNA encoding coxsackievirus A21 (CVA21) was transcribed from plasmid DNA using T7 polymerase. Within 48 hours of injecting this RNA into KAS6/1 myeloma xenografts, high titers of infectious CVA21 virions were detected in the bloodstream. Tumors regressed rapidly thereafter and mice developed signs of myositis. At euthanasia, CVA21 was recovered from regressing tumors and from skeletal muscles. Treatment outcomes were comparable following intratumoral injection of naked RNA or fully infectious CVA21 virus. Dose-response studies showed that an effective oncolytic infection could be established by intratumoral injection of 1μg of infectious RNA. The oncolytic infection could also be initiated by intravenous injection of infectious RNA. Our study demonstrates that INA is a highly promising alternative drug formulation for oncolytic virotherapy.

AB - The feasibility of using a nonviral vector formulation to initiate an oncolytic viral infection has not been previously demonstrated. We therefore sought to determine whether infectious nucleic acid (INA) could be used in place of virus particles to initiate an oncolytic picornavirus infection in vivo. Infectious RNA encoding coxsackievirus A21 (CVA21) was transcribed from plasmid DNA using T7 polymerase. Within 48 hours of injecting this RNA into KAS6/1 myeloma xenografts, high titers of infectious CVA21 virions were detected in the bloodstream. Tumors regressed rapidly thereafter and mice developed signs of myositis. At euthanasia, CVA21 was recovered from regressing tumors and from skeletal muscles. Treatment outcomes were comparable following intratumoral injection of naked RNA or fully infectious CVA21 virus. Dose-response studies showed that an effective oncolytic infection could be established by intratumoral injection of 1μg of infectious RNA. The oncolytic infection could also be initiated by intravenous injection of infectious RNA. Our study demonstrates that INA is a highly promising alternative drug formulation for oncolytic virotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85027956480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027956480&partnerID=8YFLogxK

U2 - 10.1038/mt.2011.68

DO - 10.1038/mt.2011.68

M3 - Article

AN - SCOPUS:85027956480

VL - 19

SP - 1041

EP - 1047

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 6

ER -